- Company
- Leclza’s partner ‘Rybrevant’ lands in Big 5 hospitals
- by Eo, Yun-Ho Feb 17, 2023 05:50am
- The anticancer drug Rybrevant which targets a small number of lung cancer patients has landed at general hospitals in Korea. According to industry sources, Janssen Korea’s Rybrevant (amivantamab), which is used to treat EGFR exon 20 insertion non-small-cell lung cancer (NSCLC) that is insensitive to currently available EGFR tyrosine kin
- Company
- Samsung Bioepis Soliris patent partially invalidated
- by Kim, Jin-Gu Feb 16, 2023 05:52am
- Samsung Bioepis succeeded in partially invalidating the 'Solaris patent. A blue light has been turned on for the release of the Soliris biosimilar this year. According to the pharmaceutical industry on the 13th, the Korean Intellectual Property Tribunal ruled in favor of Samsung Bioepis and ruled in favor of Samsung Bioepis in the invalidatio
- Company
- Open Innovation Trend
- by Jung, Sae-Im Feb 16, 2023 05:52am
- China is pushing for a policy to restrict its biopharmaceutical technology from escaping abroad. In the pharmaceutical industry, where open innovation has become a trend, the U.S. and China are taking the opposite step by fighting for technological supremacy. According to a report published by the Bioeconomic Research Center of the Korea
- Company
- Sorrento Theraputics Inc. filed for bankruptcy protection
- by Hwang, Jin-joon Feb 16, 2023 05:51am
- Sorrento Theraputics Inc., a U.S. bio company invested by Yuhan Corporation, filed for bankruptcy protection in the Southern Texas Bankruptcy Court. Bankruptcy protection is a system similar to Korean court receivership. Sorrento Theraputics Inc. recently lost a damage suit worth 222 billion won, resulting in a short-term cash liquidity crisi
- Company
- Exports of Dong-A ST’s anemia biosimilar exceed KRW 10 bil
- by Chon, Seung-Hyun Feb 16, 2023 05:51am
- The first biosimilar developed by Dong-A ST has made over KRW 10 billion in exports for 2 consecutive years. The cumulative export sales amount of the drug reached KRW 35.6 billion only 3 years after the drug entered the Japanese market. According to Dong-A ST on the 1st, the overseas sales of ‘Darbepoetin-α’ last year recorded KRW 13.3 bi
- Company
- Will Piqray benefit be successful again?
- by Eo, Yun-Ho Feb 16, 2023 05:50am
- Attention is focusing on whether Piqray, a PIK3CA gene target anticancer drug, can succeed in re-challenge insurance benefits. According to related industries, Novartis Korea's breast cancer treatment Piqray is expected to be presented to the HIRA Cancer Disease Review Committee in March. The drug failed to pass the deliberation committee onc
- Company
- Astellas Korea appoints Junil Kim as new head
- by Eo, Yun-Ho Feb 15, 2023 05:59am
- Astellas Pharma Korea will now be run by a Korean head. According to industry sources, Junil Kim (50) was appointed to succeed Marker Weber and head the Korean subsidiary of Astellas Pharma. With the appointment, Astellas Korea will be welcoming the first Korean head in 7 years since the resignation of Jung Hae-doh in 2017. After Jung,
- Company
- Dementia with Lewy bodies rises as a new blue ocean
- by Feb 15, 2023 05:58am
- Dementia with Lewy bodies (DLB), the second most common type of neurodegenerative disease, is expected to rise as a blue ocean in the development of diagnostics and treatments for dementia. DLB has the limitation of being difficult to diagnose in the field as no clear diagnostic method has been developed for the disease. In the industry,
- Company
- GSK immuno-cancer drug Jemperli begins free supply in Korea
- by Eo, Yun-Ho Feb 14, 2023 05:49am
- GSK has launched a free supply program for the immuno-cancer drug Jemperli. According to related industries, GSK Korea is currently conducting Expanded Access Program (EAP) at 15 major medical institutions. Unlike the same type of immuno-cancer drug, Jemperli, a PD-1 inhibitor, plans to provide a first prescription opportunity to patients wh
- Company
- SK Plasma is exclusively selling Dacogen in Korea
- by Chon, Seung-Hyun Feb 14, 2023 05:48am
- SK Plasma announced on the 13th that it has signed an exclusive domestic sales contract with Janssen Korea for the treatment of myeloid dysplasia syndrome and acute myeloid leukemia. Under the agreement, SK Plasma will be in charge of the domestic distribution and marketing of Dakogen, while Janssen Korea will be in charge of producing and
